

# EU Population-Based Cross-Sectional Survey in Migraine: ObserVational survey of the Epidemiology, tReatment and Care Of Migraine (EU OVERCOME)

**First published:** 08/09/2020

**Last updated:** 23/04/2024

Study

Planned

## Administrative details

### EU PAS number

EUPAS37093

### Study ID

37094

### DARWIN EU® study

No

### Study countries

☐ Germany

☐ Spain



## Study description

This study is a non-interventional, cross-sectional observational study with data collected via a web-based survey. Research question and objectives: Describe diagnosis, barriers to treatment and pharmacological patterns, as well as non-pharmacological treatment patterns of people with migraine in Spain and Germany who meet the International Classification of Headache Disorders (ICHD)-3 criteria. Secondary objectives aim to evaluate people with migraine regarding certain co-morbidities and migraine risk factors, to understand behavior and symptom severity during their attack, and specifics of attack treatment. The impact of migraine on private and social life will also be evaluated. Furthermore, comparative analyses will be done comparing people with migraine on novel treatments with those on SOC treatments for migraine, looking how novel treatments for migraine influence various clinical, humanistic, and economic outcomes. Subgroups analyses may include comparisons according to different frequency of monthly headache days 0-3, 4-7, 8-14,  $\geq 15$ . Population: This study will include adult members of a web-survey panel living in Spain and Germany, who meet inclusion and exclusion criteria and who agree to participate. Participants with migraines meeting the ICHD-3 screening criteria will be included in the migraine cohort. Those who do not meet the screening criteria may be included in the non-migraine cohort. Participants who are less than 18 years old, unwilling or unable to provide informed consent, or unable to read and write Spanish or German will be excluded from participation. Variables: Broad range of variables including demographics, health status, medication use, non-pharmacological behavioural treatments, migraine attack frequency/severity, migraine symptoms, quality of life, healthcare resource utilization, barriers to care seeking, stigma Data sources/Data Collection: Web-based survey

---

## Study status

Planned

## Research institutions and networks



# Institutions

Kantar Health

**First published:** 01/02/2024

**Last updated:** 01/02/2024

Institution

CRO on behalf of the Sponsor: Eli Lilly & Company

## Contact details

### Study institution contact

Treuer Tamas treuert@lilly.com

Study contact

[treuert@lilly.com](mailto:treuert@lilly.com)

### Primary lead investigator

Treuer Tamas

Primary lead investigator

## Study timelines

### Date when funding contract was signed

Planned: 15/05/2020



Actual: 15/05/2020

---

**Study start date**

Planned: 15/10/2020

---

**Date of final study report**

Planned: 31/03/2020

## Sources of funding

- Pharmaceutical company and other private sector

## More details on funding

Eli Lilly & Company

## Regulatory

**Was the study required by a regulatory body?**

No

---

**Is the study required by a Risk Management Plan (RMP)?**

Not applicable

## Methodological aspects

### Study type

### Study type list



**Study type:**

Non-interventional study

---

**Scope of the study:**

Disease epidemiology

Other

**If 'other', further details on the scope of the study**

To describe diagnosis, barriers to treatment and pharmacological patterns and non-pharmacological treatment patterns of people with migraine in Spain and Germany who meet the International Classification of Headache Disorders (ICHD)-3 criteria.

**Main study objective:**

Research question and objectives: Describe diagnosis, barriers to treatment and pharmacological patterns, as well as non-pharmacological treatment patterns of people with migraine in Spain and Germany who meet the International Classification of Headache Disorders (ICHD)-3 criteria. Secondary objectives aim to evaluate people with migraine regarding certain co-morbidities and migraine risk factors

## Study Design

**Non-interventional study design**

Cross-sectional

Other

---

**Non-interventional study design, other**

This study is a non-interventional, cross-sectional observational study with data collected via a web-based survey

## Study drug and medical condition



## **Medical condition to be studied**

Migraine

## Population studied

### **Age groups**

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

---

### **Estimated number of subjects**

22000

## Study design details

### **Outcomes**

The primary objective of this research is to understand barriers to treatment, and treatment patterns of people with migraine who met ICHD-3 criteria with subgroups of different frequency of monthly headache days 0-3, 4-7, 8-14,  $\geq 15$ .

1. Evaluate people with migraine with regard, but not limited to:

- To report the prevalence of cardiovascular related diseases and risk factors associated with migraine
- To understand the driving attitudes and behavior of people with migraine during their attack
- To understand the proportion of triptan failures and reasons for stopping
- To compare triptan responder versus insufficient

---



## Data analysis plan

Analyses are grouped into two general categories: cross-sectional cohort analyses and non-migraine population analysis. For key analyses, separate data specification plans will be developed that will provide the analytical methods in detail. For analyses, all data will be used. Descriptive statistics will be conducted to provide summaries for all variables in each cohort and specific subgroups of interest (e.g. monthly headache days). Continuous variables will be summarized as means with standard deviations, or medians and ranges, as appropriate. Categorical variables will be summarized as frequencies and percentages.

## Data management

### ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

## Data sources

### Data sources (types)

[Non-interventional study](#)

[Other](#)

---



**Data sources (types), other**

Non-interventional, cross-sectional observational study with data collected via a web-based survey

## Use of a Common Data Model (CDM)

**CDM mapping**

No

## Data quality specifications

**Check conformance**

Unknown

---

**Check completeness**

Unknown

---

**Check stability**

Unknown

---

**Check logical consistency**

Unknown

## Data characterisation

**Data characterisation conducted**

No